Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 or older
- Can read and speak English at or above the 6th grade level
- Diagnosis of neurofibromatosis type 1, neurofibromatosis type 2, or schwannomatosis
Exclusion Criteria:
- Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality)
- Unable or unwilling to participate
- Unable or unwilling to complete psychological assessments online via the REDCap or Assessment Center systems.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Satisfaction Questionnaires
After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale. Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap. |
All subjects will complete baseline psychological assessments prior to their medical visit.
Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Baseline (pre-medical visit)
|
A battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy.
|
Baseline (pre-medical visit)
|
|
Functional, Communicative and Critical Health Literacy (FFFHL) scale
Time Frame: Baseline (pre-medical visit)
|
Measures one's health literacy, the capacity of individuals to access, understand, and use health information to make informed and appropriate health-related decisions.
|
Baseline (pre-medical visit)
|
|
Medical Interview Satisfaction Scale (MISS)
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Measures patient satisfaction with individual doctor-patient consultations.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
|
Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Asks patients to report on and evaluate their experiences with health care.
This survey covers topics that are important to consumers and focus on aspects of quality that consumers are best qualified to assess, such as the communication skills of providers and ease of access to health care services.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Age, Gender, Ethnicity, and Race of Patients with NF
Time Frame: Baseline (pre-medical visit)
|
The questionnaire asks for the patient's age, gender, ethnicity, and race as part of the basic demographics.
|
Baseline (pre-medical visit)
|
|
Visual Analog Health Scale
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Measures one's current health on a scale from 0 ("very poor") to 10 ("very good").
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
|
Learning Disabilities of Patients with NF
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
This question asks patients if they have ever been diagnosed with a learning disability.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
|
First Time at NF Clinic
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
This question asks the patient if it's their first time at the MGH NF clinic.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
Other Study ID Numbers
Other Study ID Numbers
- 2014P002755
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurofibromatosis
-
NCT06961565RecruitingNeurofibroma, Plexiform | Neurofibroma Plexiform | Neurofibromatosis Type 1 (NF1) | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) | NF1 Mutation
-
NCT02096471CompletedNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
-
NCT06934928SuspendedNeurofibromatosis 1 (NF1) | Neurofibromatosis Type I
-
NCT01968590TerminatedNeurofibromatosis Type 1 (NF1)
-
NCT05581511Active, not recruitingNeurofibromatosis 1 | Neurofibromatosis Type 1 | Cutaneous Neurofibroma | Neurofibromatosis (Nonmalignant)
-
NCT00727233CompletedPlexiform Neurofibroma | Neurofibromatosis Type I
-
NCT03962543Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)
-
NCT03649165CompletedHealthy Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
-
NCT01419639CompletedNeurofibromatosis Type II
-
NCT01365468TerminatedPlexiform Neurofibroma Associated With Neurofibromatosis Type 1
Clinical Trials on Questionnaires
-
NCT00712569Completed
-
NCT07578272Not yet recruiting
-
NCT04893070Completed
-
NCT06290115Not yet recruiting
-
NCT05587595RecruitingIntensive Care Unit Syndrome | Pediatric Post-intensive Care Syndrome
-
NCT06831240Not yet recruitingStroke | Amputation | Spinal Cord Injury | Caregivers | Wheelchair Users | Wheelchair Service Providers
-
NCT02957565CompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple Sites
-
NCT02928731Completed
-
NCT03699501Completed
-
NCT05755347CompletedBreast Cancer | Metastasis